Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

9
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
9
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

11
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
11
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

21
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
21
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

9
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs but also impacts other areas, such as the arms, thereby impairing overall circulation and organ function.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty deposits inside the arterial...
9
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

14
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
14

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving Health Equity in Hypertension Control for Black Patients.

Joint Commission journal on quality and patient safety·2026
Same author

Use of a polygenic risk score to enhance early detection of coronary atherosclerosis.

American journal of preventive cardiology·2026
Same author

Retinal OCTA-derived microvascular remodeling is associated with coronary microvascular dysfunction in women with ischemia and no obstructive coronary artery disease: A pilot study.

American journal of preventive cardiology·2026
Same author

Lymphocyte-Platelet and Neutrophil-Platelet Aggregates are Associated with Dysregulated Platelet Inflammatory Pathways in Psoriasis.

Journal of psoriasis and psoriatic arthritis·2026
Same author

Expert Opinion: Restrictions, Precautions, or Normalcy? Defining Everyday Risk in Patients Treated With IL-1 Blockers for Recurrent Pericarditis.

Journal of cardiovascular pharmacology·2026
Same author

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026

Related Experiment Video

Updated: Jul 15, 2025

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

13.8K

Atherosclerosis in Systemic Lupus Erythematosus.

Rachel Tobin1, Nidhi Patel2, Kardie Tobb3

  • 1Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. rstobin@emory.edu.

Current Atherosclerosis Reports
|September 28, 2023
PubMed
Summary

Systemic lupus erythematosus (SLE) patients face higher cardiovascular disease (CVD) risks. Traditional tools often miss this, necessitating early detection and management strategies for atherosclerosis in SLE.

Keywords:
AtherosclerosisCoronary microvascular diseaseInflammation and cardiovascular diseaseLupus treatmentSystemic lupus erythematosus

More Related Videos

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

37.6K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.0K

Related Experiment Videos

Last Updated: Jul 15, 2025

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

13.8K
Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

37.6K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.0K

Area of Science:

  • Rheumatology
  • Cardiology
  • Immunology

Background:

  • Systemic lupus erythematosus (SLE) patients exhibit a significantly elevated risk of cardiovascular disease (CVD) compared to the general population.
  • This increased risk is notable in young female patients, a demographic not typically assessed as high-risk by conventional cardiovascular disease assessment tools.
  • Traditional risk models frequently underestimate the cardiovascular risk in SLE patients, highlighting a critical gap in patient evaluation.

Purpose of the Study:

  • To elucidate the complex pathophysiology of atherosclerosis development in patients with SLE.
  • To enhance clinical awareness regarding the intricate relationship between SLE and the heightened incidence of CVD.
  • To underscore the need for specialized approaches in assessing cardiovascular risk within the SLE cohort.

Main Methods:

  • Review of current literature on SLE and cardiovascular disease pathophysiology.
  • Analysis of factors contributing to accelerated atherosclerosis in SLE patients.
  • Discussion of the limitations of conventional cardiovascular risk assessment tools in SLE.

Main Results:

  • Cardiovascular disease risk in SLE is multifactorial, involving proatherogenic lipid profiles, immune dysregulation, inflammation, treatment side effects, and microvascular dysfunction.
  • Conventional cardiovascular risk models demonstrate suboptimal performance in identifying SLE patients with high atherosclerosis risk.
  • Non-invasive imaging techniques are crucial for detecting subclinical CVD in SLE patients, enabling proactive risk factor management.

Conclusions:

  • SLE patients face an increased burden of atherosclerotic CVD not fully explained by traditional risk factors.
  • Early identification and aggressive management of cardiovascular risk factors are imperative for SLE patients.
  • Clinicians must be vigilant for the association between SLE and accelerated atherosclerosis to ensure timely diagnosis and treatment, thereby improving patient outcomes.